Bonti Announces Hot Topics Presentation Featuring EB-001 At Plastic Surgery The Meeting
Published: Oct 09, 2017
Positive Phase 2 Proof of Concept Clinical Data Paves the Way for Therapeutic Musculoskeletal Pain Management and for Further Facial Aesthetic Studies
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Bonti, a privately-held, clinical-stage biotechnology company, today announced a Hot Topics presentation featuring proof of concept clinical results for its lead product EB-001 at Plastic Surgery The Meeting on October 6th in Orlando, FL. Dr. Brian Kinney presented EB-001 study findings and their clinical and commercial significance at this premier educational and networking event which was organized by the American Society of Plastic Surgeons (ASPS), The Plastic Surgery Foundation (The PFS) and The American Society of Maxillofacial Surgeons (ASMS). EB-001 is a novel serotype E botulinum neurotoxin (BoNT/E) with a unique product profile, characterized by fast onset of action (within 24 hours) and short duration of effect (about 4 weeks). With the benefits of this profile in mind, EB-001 is being developed for therapeutic and aesthetic indications with significant addressable market opportunities.
Dr. Kinney, a board-certified plastic surgeon, whose practice is in Beverly Hills, CA, and a Clinical Associate Professor of Plastic Surgery at the University of Southern California (USC), spotlighted Phase 2 proof of concept clinical data illustrating that, as previously announced, the first in human EB-001 study achieved its objectives and confirmed both the favorable safety and the expected clinical efficacy profile. He addressed how EB-001 is being developed to establish it for exclusive and complementary facial aesthetic uses with unmet needs. Dr. Kinney also outlined how the dosing data from the proof of concept study confirmed dose selection so Bonti could start the therapeutic LANTERN-1 Phase 2 clinical study evaluating EB-001 in reducing musculoskeletal pain.
“We’re grateful to the ASPS for selecting EB-001 for the Hot Topics track and we were privileged to have Dr. Kinney share EB-001’s potential prospects for both therapeutic and aesthetic applications with his peers in the plastic surgery community attending this prestigious conference,” commented Fauad Hasan, CEO at Bonti. “We believe EB-001 will help expand the aesthetic market by serving as an additional tool for plastic surgeons looking for innovative ways to address their patients’ facial aesthetic needs not tackled by current marketed products. Furthermore, EB-001 also has the potential to be a long-acting, non-opioid solution for treating focal musculoskeletal pain resulting after various plastic and reconstructive surgeries, which account for about 15% of our approximately 12 million target surgical procedures each year in the U.S.”
“My excitement surrounding EB-001 is based on the strong clinical proof of concept data which may conceivably lead to new treatment paradigms,” said Dr. Kinney, a world renowned, board-certified plastic surgeon, past member of the Board of Directors of the American Society of Plastic Surgeons and a Past President of the Plastic Surgery Educational Foundation of the United States. “Both the pain relief and the aesthetic applications for EB-001 may be game changing because of the potential benefits delivered by the drug’s unique fast onset and short duration target clinical profile. EB-001 may be a significant addition to our post-surgical multi-modal pain management options to treat pain effectively while helping to address the opioid epidemic. And from a cosmetic perspective, the prospect for EB-001 to solve current problems so patients look their best and have the highest satisfaction possible is promising.”
Bonti’s lead product candidate, EB-001, is an investigational botulinum neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar to the marketed botulinum neurotoxin serotype A (BoNT/A) products though it has a differentiated clinical profile. EB-001 has a fast onset of action (within 24 hours) and short duration of effect (about 4 weeks). Currently marketed BoNT/A products have an onset of action around 3-7 days and a duration of effect around 3-4 months. The unique target clinical profile of EB-001 may be well suited for a vast range of aesthetic and therapeutic uses, including for the treatment of post-surgical and non-surgical musculoskeletal pain, with currently unmet needs.
Bonti, based in Newport Beach, California, is a rapidly emerging biotechnology company founded by world class neurotoxin experts with proven success at Allergan, one of the Fortune 500 fastest growing pharma companies. This team, with unsurpassed neurotoxin, aesthetic and pain expertise, is uniquely qualified to develop unprecedented treatment paradigms driven by a novel neurotoxin platform to become an innovative leader in both aesthetic and therapeutic markets. By turning the science of neurotoxins into beneficial patient and healthcare provider solutions, Bonti will improve lives by successfully addressing key unmet needs in markets with significant addressable opportunities.
For more information, please visit http://bonti.com.
Orlando Rodrigues, 760-212-5727